The MPN Hub were pleased to speak to Jean-Jacques Kiladjian, University of Paris, Paris, FR, during the 61st American Society of Hematology (ASH) meeting in Orlando, US. Based on the PROUD-PV/CONTINUATION-PV studies, we asked: What are the benefits of ropeginterferon alpha-2b for the treatment of polycythemia vera?
Jean-Jacques Kiladjian discusses the results of the phase III, randomized, PROUD-PV and its extension study, CONTINUATION-PV, in patients with polycythemia vera in need of a cytoreductive treatment such as the long-acting ropeginterferon alpha-2b. He explains the response rates, clinical benefits and superiority of the ropeginterferon alpha-2b treatment against the comparator arm.
Ещё видео!